carvedilol has been researched along with Arrhythmia in 43 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "To investigate the effect of low-dose carvedilol combined with candesartan in the prevention of acute and chronic cardiotoxicity of anthracycline drugs in adjuvant chemotherapy of breast cancer." | 9.17 | [Preventive effect of low-dose carvedilol combined with candesartan on the cardiotoxicity of anthracycline drugs in the adjuvant chemotherapy of breast cancer]. ( Han, YL; Liang, XF; Liu, L; Liu, YY; Liu, ZZ; Xie, XD; Zheng, ZD, 2013) |
| "To investigate the effects of carvedilol and metoprolol on the expression of autoantibodies against cardiac β(1), β(2) and α(1) adrenergic receptors in aged patients with chronic heart failure (CHF) and ventricular arrhythmia (VA)." | 9.14 | [Effects of carvedilol and metoprolol on expression of autoantibodies against cardiac adrenergic receptors in aged patients with chronic heart failure and ventricular arrhythmia]. ( Li, XD; Wang, JC; Ye, L; Zhao, Y; Zhou, NN; Zhu, X, 2010) |
| "The aim of this study was investigate the effects of carvedilol therapy on ventricular repolarization characteristics as assessed by QT dispersion (QTd) and heart rate variability (HRV) in patients with heart failure." | 9.12 | Effects of carvedilol therapy on arrhythmia markers in patients with congestive heart failure. ( Akdeniz, B; Aslan, O; Badak, O; Baris, N; Göldeli, O; Guneri, S; Kirimli, O; Savas, IZ, 2006) |
| "Carvedilol is a nonselective beta-blocker with alpha-mediated vasodilating properties that has been shown to be effective in systemic hypertension, stable angina, and congestive heart failure (CHF)." | 9.07 | Effects of carvedilol on ventricular arrhythmias. ( DasGupta, P; Lahiri, A; Müller-Beckmann, B; Senior, R; van der Does, R, 1992) |
| " However, limited data exist regarding the effects of the beta-blocker (BB) carvedilol on arrhythmia and urologic outcomes in BPH patients." | 8.31 | Effects of the beta-blocker carvedilol on arrhythmia and long-term clinical outcomes in benign prostate hypertrophy patients. ( Heo, JH; Im, SI; Kang, PM; Kim, BJ; Kim, HS; Kim, SJ; Kim, TS; Park, HS, 2023) |
| "We identified that carvedilol, a β-blocker not commonly used in HCM, suppresses contractile function and arrhythmia by inhibiting RyR2 (ryanodine receptor type 2)." | 8.31 | Improved Cardiac Performance and Decreased Arrhythmia in Hypertrophic Cardiomyopathy With Non-β-Blocking R-Enantiomer Carvedilol. ( Ashley, EA; Bernstein, D; Huang, Y; Kawana, M; Kirillova, A; Lane, KV; Parikh, VN; Perez, MV; Pruitt, BL; Seo, K; Wang, Q; Wheeler, MT; Wu, JC; Yadav, S; Yamamoto, Y, 2023) |
| "This study evaluates the impact of carvedilol dose changes on the ventricular arrhythmia event rates for patients > 18 years of age with systolic heart failure and examines dose dependent effects of carvedilol withdrawal in dose reduction and discontinuation subgroups." | 7.81 | Dose Related Patterns of Ventricular Arrhythmia due to Carvedilol Withdrawal in Patients with Systolic Heart Failure. ( Anaya, P; Brouse, SD; Charnigo, RJ; Kido, K; Macaulay, TE, 2015) |
| "We conclude that the addition of carvedilol to standard therapy can improve clinical symptoms and heart rate variability, and reduce in arrhythmia markers in children with DCM." | 7.79 | Effects of carvedilol therapy on cardiac autonomic control, QT dispersion, and ventricular arrhythmias in children with dilated cardiomyopathy. ( Akdeniz, C; Balli, S; Ece, I; Kibar, AE; Oflaz, MB; Tuzcu, V, 2013) |
| "We hypothesized that carvedilol, a nonselective β-blocker, can exert antiarrhythmogenic effects by inhibiting sympathetic nerve sprouting and electrical remodeling at peri-infarct zones after myocardial infarction (MI)." | 7.76 | Carvedilol ameliorates sympathetic nerve sprouting and electrical remodeling after myocardial infarction in rats. ( He, B; Hu, X; Huang, C; Jiang, H; Lu, Z; Tang, Q; Wen, H, 2010) |
| "These results indicate that carvedilol has the inhibitory effect against reperfusion arrhythmias in rats and suggest that the mechanism of action of this compound is related to the combined effects of beta-blocking and antioxidant." | 7.70 | The inhibitory effects of carvedilol against arrhythmias induced by coronary reperfusion in anesthetized rats. ( Ijiri, H; Ishihara, T; Kohno, I; Komori, S; Matsumura, K; Osada, M; Sawanobori, T; Takusagawa, M; Tamura, K; Umetani, K, 2000) |
| "Ventricular and atrial arrhythmias are common after acute myocardial infarction (AMI) and are associated with a poor prognosis." | 6.71 | Antiarrhythmic effect of carvedilol after acute myocardial infarction: results of the Carvedilol Post-Infarct Survival Control in Left Ventricular Dysfunction (CAPRICORN) trial. ( Colucci, W; Dargie, H; Ford, I; Køber, L; Lopez-Sendon, J; McMurray, J; Remme, W; Robertson, M; Sharpe, DN, 2005) |
| "Carvedilol is a beta- and alpha-adrenergic-blocking drug with clinically important antiarrhythmic properties." | 6.43 | Carvedilol's antiarrhythmic properties: therapeutic implications in patients with left ventricular dysfunction. ( Lukas, MA; Naccarelli, GV, 2005) |
| "To investigate the effect of low-dose carvedilol combined with candesartan in the prevention of acute and chronic cardiotoxicity of anthracycline drugs in adjuvant chemotherapy of breast cancer." | 5.17 | [Preventive effect of low-dose carvedilol combined with candesartan on the cardiotoxicity of anthracycline drugs in the adjuvant chemotherapy of breast cancer]. ( Han, YL; Liang, XF; Liu, L; Liu, YY; Liu, ZZ; Xie, XD; Zheng, ZD, 2013) |
| "To investigate the effects of carvedilol and metoprolol on the expression of autoantibodies against cardiac β(1), β(2) and α(1) adrenergic receptors in aged patients with chronic heart failure (CHF) and ventricular arrhythmia (VA)." | 5.14 | [Effects of carvedilol and metoprolol on expression of autoantibodies against cardiac adrenergic receptors in aged patients with chronic heart failure and ventricular arrhythmia]. ( Li, XD; Wang, JC; Ye, L; Zhao, Y; Zhou, NN; Zhu, X, 2010) |
| "The aim of this study was investigate the effects of carvedilol therapy on ventricular repolarization characteristics as assessed by QT dispersion (QTd) and heart rate variability (HRV) in patients with heart failure." | 5.12 | Effects of carvedilol therapy on arrhythmia markers in patients with congestive heart failure. ( Akdeniz, B; Aslan, O; Badak, O; Baris, N; Göldeli, O; Guneri, S; Kirimli, O; Savas, IZ, 2006) |
| "Carvedilol is a nonselective beta-blocker with alpha-mediated vasodilating properties that has been shown to be effective in systemic hypertension, stable angina, and congestive heart failure (CHF)." | 5.07 | Effects of carvedilol on ventricular arrhythmias. ( DasGupta, P; Lahiri, A; Müller-Beckmann, B; Senior, R; van der Does, R, 1992) |
| "Carvedilol is an adrenergic antagonist with nonselective beta- and a1-receptor blocking properties that has demonstrated significant clinical benefit in the management of patients with heart failure and in the post-myocardial infarction setting." | 4.82 | Carvedilol: beta-blockade and beyond. ( Gheorghiade, M; Stroe, AF, 2004) |
| " However, limited data exist regarding the effects of the beta-blocker (BB) carvedilol on arrhythmia and urologic outcomes in BPH patients." | 4.31 | Effects of the beta-blocker carvedilol on arrhythmia and long-term clinical outcomes in benign prostate hypertrophy patients. ( Heo, JH; Im, SI; Kang, PM; Kim, BJ; Kim, HS; Kim, SJ; Kim, TS; Park, HS, 2023) |
| "We identified that carvedilol, a β-blocker not commonly used in HCM, suppresses contractile function and arrhythmia by inhibiting RyR2 (ryanodine receptor type 2)." | 4.31 | Improved Cardiac Performance and Decreased Arrhythmia in Hypertrophic Cardiomyopathy With Non-β-Blocking R-Enantiomer Carvedilol. ( Ashley, EA; Bernstein, D; Huang, Y; Kawana, M; Kirillova, A; Lane, KV; Parikh, VN; Perez, MV; Pruitt, BL; Seo, K; Wang, Q; Wheeler, MT; Wu, JC; Yadav, S; Yamamoto, Y, 2023) |
| "This study evaluates the impact of carvedilol dose changes on the ventricular arrhythmia event rates for patients > 18 years of age with systolic heart failure and examines dose dependent effects of carvedilol withdrawal in dose reduction and discontinuation subgroups." | 3.81 | Dose Related Patterns of Ventricular Arrhythmia due to Carvedilol Withdrawal in Patients with Systolic Heart Failure. ( Anaya, P; Brouse, SD; Charnigo, RJ; Kido, K; Macaulay, TE, 2015) |
| "We conclude that the addition of carvedilol to standard therapy can improve clinical symptoms and heart rate variability, and reduce in arrhythmia markers in children with DCM." | 3.79 | Effects of carvedilol therapy on cardiac autonomic control, QT dispersion, and ventricular arrhythmias in children with dilated cardiomyopathy. ( Akdeniz, C; Balli, S; Ece, I; Kibar, AE; Oflaz, MB; Tuzcu, V, 2013) |
| "Carvedilol is one of the most effective beta blockers for preventing ventricular tachyarrhythmias in heart failure, but the mechanisms underlying its favorable antiarrhythmic benefits remain unclear." | 3.77 | Carvedilol and its new analogs suppress arrhythmogenic store overload-induced Ca2+ release. ( Back, TG; Chen, H; Chen, J; Chen, SR; Chen, W; Cheng, H; Duff, HJ; Feldman, AM; Fill, M; Gillis, AM; Guo, A; Jiang, D; Jones, PP; Li, X; Smith, CD; Song, LS; Tian, X; Vembaiyan, K; Wang, A; Wang, R; Xiao, J; Xie, C; Yang, D; Zhang, J; Zhang, L; Zhong, X; Zhou, Q; Zhu, W, 2011) |
| "We hypothesized that carvedilol, a nonselective β-blocker, can exert antiarrhythmogenic effects by inhibiting sympathetic nerve sprouting and electrical remodeling at peri-infarct zones after myocardial infarction (MI)." | 3.76 | Carvedilol ameliorates sympathetic nerve sprouting and electrical remodeling after myocardial infarction in rats. ( He, B; Hu, X; Huang, C; Jiang, H; Lu, Z; Tang, Q; Wen, H, 2010) |
| "Baroreflex sensitivity was assessed in 287 patients with history of myocardial infarction and left ventricular ejection fraction < or =40% by phenylephrine test and was found to be depressed (4." | 3.72 | [Correction of baroreflex sensitivity impairment and efficacy of prevention of sudden arrhythmic death in patients with postinfarction left ventricular dysfunction]. ( Bozhko, AA; Kanopskiĭ, SG; Staritskiĭ, AG, 2004) |
| "These results indicate that carvedilol has the inhibitory effect against reperfusion arrhythmias in rats and suggest that the mechanism of action of this compound is related to the combined effects of beta-blocking and antioxidant." | 3.70 | The inhibitory effects of carvedilol against arrhythmias induced by coronary reperfusion in anesthetized rats. ( Ijiri, H; Ishihara, T; Kohno, I; Komori, S; Matsumura, K; Osada, M; Sawanobori, T; Takusagawa, M; Tamura, K; Umetani, K, 2000) |
| "Ventricular and atrial arrhythmias are common after acute myocardial infarction (AMI) and are associated with a poor prognosis." | 2.71 | Antiarrhythmic effect of carvedilol after acute myocardial infarction: results of the Carvedilol Post-Infarct Survival Control in Left Ventricular Dysfunction (CAPRICORN) trial. ( Colucci, W; Dargie, H; Ford, I; Køber, L; Lopez-Sendon, J; McMurray, J; Remme, W; Robertson, M; Sharpe, DN, 2005) |
| "Carvedilol is a non-selective β-blocker with α₁-adrenergic receptor antagonism properties." | 2.48 | A critical review of the use of carvedilol in ischemic heart disease. ( Abrencillo, R; Chen-Scarabelli, C; Di Rezze, J; Faggian, G; Gardin, T; Gidwani, UK; Murad, Y; Qureshi, W; Saravolatz, L; Scarabelli, TM; Shieh, WS, 2012) |
| "Carvedilol is a beta- and alpha-adrenergic-blocking drug with clinically important antiarrhythmic properties." | 2.43 | Carvedilol's antiarrhythmic properties: therapeutic implications in patients with left ventricular dysfunction. ( Lukas, MA; Naccarelli, GV, 2005) |
| " Carvedilol can be added to Amiodarone in patients with severe ventricular rhythm disorders and increased risk of sudden death without expecting of increase adverse events (than either drug alone) or loss of clinical efficacy." | 1.46 | THE SAFETY AND EFFICACY OF AMIODARONE AND CARVEDILOL COMBINATION IN TREATMENT OF PATIENTS WITH SEVERE CARDIAC RHYTHM DISORDERS. ( Khintibidze, I; Tsetskhladze, E, 2017) |
| " Beta-blocker dosages were titrated, and three patients achieved the target beta-blocker dosage established for stage A-C heart failure." | 1.34 | Tolerability of beta-blockers in outpatients with refractory heart failure who were receiving continuous milrinone. ( Earl, GL; Fitzpatrick, JM; Narula, J; Verbos-Kazanas, MA, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (6.98) | 18.2507 |
| 2000's | 21 (48.84) | 29.6817 |
| 2010's | 14 (32.56) | 24.3611 |
| 2020's | 5 (11.63) | 2.80 |
| Authors | Studies |
|---|---|
| Jia, L | 1 |
| Sun, H | 1 |
| Groszek, G | 1 |
| Bednarski, M | 1 |
| Dybała, M | 1 |
| Filipek, B | 2 |
| Szkaradek, N | 1 |
| Rapacz, A | 1 |
| Pytka, K | 1 |
| Siwek, A | 1 |
| Cegła, M | 1 |
| Marona, H | 1 |
| Vivier, D | 1 |
| Bennis, K | 1 |
| Lesage, F | 1 |
| Ducki, S | 1 |
| Robinson, VM | 1 |
| Alsalahat, I | 1 |
| Freeman, S | 1 |
| Antzelevitch, C | 1 |
| Barajas-Martinez, H | 1 |
| Venetucci, L | 1 |
| Kim, SJ | 1 |
| Park, HS | 1 |
| Kang, PM | 1 |
| Kim, BJ | 1 |
| Kim, HS | 1 |
| Heo, JH | 1 |
| Kim, TS | 1 |
| Im, SI | 1 |
| Seo, K | 1 |
| Yamamoto, Y | 1 |
| Kirillova, A | 1 |
| Kawana, M | 1 |
| Yadav, S | 1 |
| Huang, Y | 1 |
| Wang, Q | 1 |
| Lane, KV | 1 |
| Pruitt, BL | 1 |
| Perez, MV | 1 |
| Bernstein, D | 1 |
| Wu, JC | 1 |
| Wheeler, MT | 1 |
| Parikh, VN | 1 |
| Ashley, EA | 1 |
| Muhailan, M | 1 |
| Al-Shbool, G | 1 |
| Zhang, JG | 1 |
| Dai, SP | 1 |
| Liu, H | 1 |
| Xu, ZS | 1 |
| Tsetskhladze, E | 1 |
| Khintibidze, I | 1 |
| Oflaz, MB | 1 |
| Balli, S | 1 |
| Kibar, AE | 1 |
| Ece, I | 1 |
| Akdeniz, C | 1 |
| Tuzcu, V | 1 |
| Bodi, I | 1 |
| Franke, G | 1 |
| Pantulu, ND | 1 |
| Wu, K | 1 |
| Perez-Feliz, S | 1 |
| Bode, C | 1 |
| Zehender, M | 1 |
| zur Hausen, A | 1 |
| Brunner, M | 1 |
| Odening, KE | 1 |
| Liu, L | 1 |
| Liu, ZZ | 1 |
| Liu, YY | 1 |
| Zheng, ZD | 1 |
| Liang, XF | 1 |
| Han, YL | 1 |
| Xie, XD | 1 |
| Kido, K | 1 |
| Brouse, SD | 1 |
| Macaulay, TE | 1 |
| Charnigo, RJ | 1 |
| Anaya, P | 1 |
| Motoki, N | 1 |
| Inaba, Y | 1 |
| Matsuzaki, S | 1 |
| Akazawa, Y | 1 |
| Nishimura, T | 1 |
| Fukuyama, T | 1 |
| Koike, K | 1 |
| Tan, Z | 1 |
| Xiao, Z | 1 |
| Wei, J | 1 |
| Zhang, J | 2 |
| Zhou, Q | 2 |
| Smith, CD | 2 |
| Nani, A | 1 |
| Wu, G | 1 |
| Song, LS | 2 |
| Back, TG | 2 |
| Fill, M | 2 |
| Chen, SR | 2 |
| Wen, H | 1 |
| Jiang, H | 1 |
| Lu, Z | 1 |
| Hu, X | 1 |
| He, B | 1 |
| Tang, Q | 1 |
| Huang, C | 1 |
| Li, XD | 1 |
| Wang, JC | 1 |
| Ye, L | 1 |
| Zhao, Y | 1 |
| Zhou, NN | 1 |
| Zhu, X | 1 |
| Xiao, J | 1 |
| Jiang, D | 1 |
| Wang, R | 1 |
| Vembaiyan, K | 1 |
| Wang, A | 1 |
| Xie, C | 1 |
| Chen, W | 1 |
| Tian, X | 1 |
| Jones, PP | 1 |
| Zhong, X | 1 |
| Guo, A | 1 |
| Chen, H | 1 |
| Zhang, L | 1 |
| Zhu, W | 1 |
| Yang, D | 1 |
| Li, X | 1 |
| Chen, J | 1 |
| Gillis, AM | 1 |
| Duff, HJ | 1 |
| Cheng, H | 1 |
| Feldman, AM | 1 |
| Knollmann, BC | 1 |
| Chen-Scarabelli, C | 1 |
| Saravolatz, L | 2 |
| Murad, Y | 1 |
| Shieh, WS | 1 |
| Qureshi, W | 1 |
| Di Rezze, J | 1 |
| Abrencillo, R | 1 |
| Gardin, T | 1 |
| Gidwani, UK | 1 |
| Faggian, G | 1 |
| Scarabelli, TM | 1 |
| Piccirillo, G | 1 |
| Quaglione, R | 1 |
| Nocco, M | 1 |
| Naso, C | 1 |
| Moisè, A | 1 |
| Lionetti, M | 1 |
| Di Carlo, S | 1 |
| Marigliano, V | 1 |
| Coca, SG | 1 |
| Buller, GK | 1 |
| Liebson, PR | 1 |
| Stroe, AF | 1 |
| Gheorghiade, M | 1 |
| Kanopskiĭ, SG | 1 |
| Staritskiĭ, AG | 1 |
| Bozhko, AA | 1 |
| Anh, D | 1 |
| Marine, JE | 1 |
| McMurray, J | 1 |
| Køber, L | 1 |
| Robertson, M | 1 |
| Dargie, H | 1 |
| Colucci, W | 1 |
| Lopez-Sendon, J | 1 |
| Remme, W | 1 |
| Sharpe, DN | 1 |
| Ford, I | 1 |
| Pratt, CM | 1 |
| Naccarelli, GV | 2 |
| Lukas, MA | 1 |
| El-Sherif, N | 1 |
| Turitto, G | 1 |
| Akdeniz, B | 1 |
| Guneri, S | 1 |
| Savas, IZ | 1 |
| Aslan, O | 1 |
| Baris, N | 1 |
| Badak, O | 1 |
| Kirimli, O | 1 |
| Göldeli, O | 1 |
| Earl, GL | 1 |
| Verbos-Kazanas, MA | 1 |
| Fitzpatrick, JM | 1 |
| Narula, J | 1 |
| Fox, K | 1 |
| Borer, JS | 1 |
| Camm, AJ | 1 |
| Danchin, N | 1 |
| Ferrari, R | 1 |
| Lopez Sendon, JL | 1 |
| Steg, PG | 1 |
| Tardif, JC | 1 |
| Tavazzi, L | 1 |
| Tendera, M | 1 |
| Fett, JD | 1 |
| Witte, KK | 1 |
| Clark, AL | 1 |
| Taylor, SH | 1 |
| Storstein, L | 2 |
| Fauchier, L | 1 |
| Giraudeau, B | 1 |
| Takusagawa, M | 1 |
| Komori, S | 1 |
| Matsumura, K | 1 |
| Osada, M | 1 |
| Kohno, I | 1 |
| Umetani, K | 1 |
| Ishihara, T | 1 |
| Sawanobori, T | 1 |
| Ijiri, H | 1 |
| Tamura, K | 1 |
| Vasil'ev, AP | 1 |
| Strel'tsova, NN | 1 |
| Gorbunova, TIu | 1 |
| Mal'tseva, IA | 1 |
| Zykova, EL | 1 |
| Senior, R | 1 |
| Müller-Beckmann, B | 1 |
| DasGupta, P | 1 |
| van der Does, R | 1 |
| Lahiri, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Single Centre, Retrospective Cohort Study on Post Analysis on the Link Between the Clinical Heart Rate and Outcomes During PCI[NCT02351674] | 15,000 participants (Anticipated) | Observational | 2015-01-31 | Not yet recruiting | |||
| Heart Rate Lowering Efficacy and Respiratory Safety of Ivabradine in Patients With Obstructive Airway Disease[NCT01365286] | Phase 4 | 40 participants (Actual) | Interventional | 2009-05-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
9 reviews available for carvedilol and Arrhythmia
| Article | Year |
|---|---|
Perspectives on the Two-Pore Domain Potassium Channel TREK-1 (TWIK-Related K(+) Channel 1). A Novel Therapeutic Target?
Topics: Arrhythmias, Cardiac; Depression; Epilepsy; Humans; Inflammation; Models, Molecular; Molecular Struc | 2016 |
A critical review of the use of carvedilol in ischemic heart disease.
Topics: Adrenergic beta-Antagonists; Angina, Stable; Animals; Anti-Arrhythmia Agents; Antioxidants; Arrhythm | 2012 |
Carvedilol: beta-blockade and beyond.
Topics: Adrenergic beta-Antagonists; Arrhythmias, Cardiac; Carbazoles; Carvedilol; Clinical Trials as Topic; | 2004 |
Beta blockers as anti-arrhythmic agents.
Topics: Adrenergic beta-Antagonists; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Carbazoles; Carvedilol; H | 2004 |
Carvedilol's antiarrhythmic properties: therapeutic implications in patients with left ventricular dysfunction.
Topics: Adrenergic alpha-Antagonists; Arrhythmias, Cardiac; Carbazoles; Carvedilol; Electrocardiography; Hea | 2005 |
Electrophysiologic effects of carvedilol: is carvedilol an antiarrhythmic agent?
Topics: Action Potentials; Adrenergic beta-Antagonists; Animals; Anti-Arrhythmia Agents; Antioxidants; Arrhy | 2005 |
Resting heart rate in cardiovascular disease.
Topics: Adrenergic beta-Antagonists; Animals; Arrhythmias, Cardiac; Calcium Channel Blockers; Carbazoles; Ca | 2007 |
Resting heart rate in cardiovascular disease.
Topics: Adrenergic beta-Antagonists; Animals; Arrhythmias, Cardiac; Calcium Channel Blockers; Carbazoles; Ca | 2007 |
Resting heart rate in cardiovascular disease.
Topics: Adrenergic beta-Antagonists; Animals; Arrhythmias, Cardiac; Calcium Channel Blockers; Carbazoles; Ca | 2007 |
Resting heart rate in cardiovascular disease.
Topics: Adrenergic beta-Antagonists; Animals; Arrhythmias, Cardiac; Calcium Channel Blockers; Carbazoles; Ca | 2007 |
Carvedilol in the treatment of elderly patients with chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Arrhythmias, Cardiac; C | 2008 |
Carvedilol--clinical experience in arrhythmias.
Topics: Adrenergic beta-Antagonists; Animals; Anti-Arrhythmia Agents; Antihypertensive Agents; Arrhythmias, | 1993 |
8 trials available for carvedilol and Arrhythmia
| Article | Year |
|---|---|
[Preventive effect of low-dose carvedilol combined with candesartan on the cardiotoxicity of anthracycline drugs in the adjuvant chemotherapy of breast cancer].
Topics: Adrenergic beta-Antagonists; Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Antineoplastic Co | 2013 |
[Effects of carvedilol and metoprolol on expression of autoantibodies against cardiac adrenergic receptors in aged patients with chronic heart failure and ventricular arrhythmia].
Topics: Aged; Aged, 80 and over; Arrhythmias, Cardiac; Autoantibodies; Carbazoles; Carvedilol; Female; Heart | 2010 |
Effects of long-term beta-blocker (metoprolol or carvedilol) therapy on QT variability in subjects with chronic heart failure secondary to ischemic cardiomyopathy.
Topics: Adrenergic beta-Antagonists; Arrhythmias, Cardiac; Carbazoles; Carvedilol; Female; Heart Failure; Hu | 2002 |
Antiarrhythmic effect of carvedilol after acute myocardial infarction: results of the Carvedilol Post-Infarct Survival Control in Left Ventricular Dysfunction (CAPRICORN) trial.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Arrhythmias, Cardiac; Carbazoles; Carve | 2005 |
Does carvedilol have antiarrhythmic properties?
Topics: Adrenergic beta-Antagonists; Arrhythmias, Cardiac; Carbazoles; Carvedilol; Follow-Up Studies; Humans | 2005 |
Effects of carvedilol therapy on arrhythmia markers in patients with congestive heart failure.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Arrhythmias, Cardiac; Carbazoles; Carve | 2006 |
[Antioxidant and antiarrhythmic activity of carvedilol in patients with ischemic heart disease. Comparison with anaprilin].
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Anti-Arrhythmia Agents; Antioxidants; Arrhythmias, Car | 2001 |
Effects of carvedilol on ventricular arrhythmias.
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Arrhythmias, Cardiac; Blood Pressure; Carbazoles; Carv | 1992 |
26 other studies available for carvedilol and Arrhythmia
| Article | Year |
|---|---|
Support vector machines classification of hERG liabilities based on atom types.
Topics: Animals; Arrhythmias, Cardiac; CHO Cells; Computer Simulation; Cricetinae; Cricetulus; Discriminant | 2008 |
Synthesis and adrenolytic activity of 1-(1H-indol-4-yloxy)-3-{[2-(2-methoxyphenoxy)ethyl]amino}propan-2-ol and its enantiomers. Part 1.
Topics: 2-Propanol; Adrenergic Antagonists; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Electroca | 2009 |
Synthesis and preliminary evaluation of pharmacological properties of some piperazine derivatives of xanthone.
Topics: Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Blood Pressure; Heart Rate; Male; Piperazine; | 2013 |
A carvedilol analogue, VK-II-86, prevents hypokalaemia-induced ventricular arrhythmia through novel multi-channel effects.
Topics: Action Potentials; Animals; Arrhythmias, Cardiac; Calcium; Carvedilol; Dantrolene; Dogs; HEK293 Cell | 2022 |
Effects of the beta-blocker carvedilol on arrhythmia and long-term clinical outcomes in benign prostate hypertrophy patients.
Topics: Adrenergic beta-Antagonists; Arrhythmias, Cardiac; Carvedilol; Humans; Hypertrophy; Male; Prostate; | 2023 |
Improved Cardiac Performance and Decreased Arrhythmia in Hypertrophic Cardiomyopathy With Non-β-Blocking R-Enantiomer Carvedilol.
Topics: Adrenergic beta-Antagonists; Animals; Arrhythmias, Cardiac; Cardiomyopathy, Hypertrophic; Carvedilol | 2023 |
Pseudo-Wellens' Syndrome Temporally Associated With Immune Check Point Inhibitors Use.
Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Angiotensin II Type 1 Receptor Blockers; Antineoplast | 2020 |
Comparison of carvedilol versus metoprolol in patients with acute myocardial infarction: A protocol for systematic review and meta-analysis.
Topics: Arrhythmias, Cardiac; Carvedilol; Death, Sudden, Cardiac; Humans; Meta-Analysis as Topic; Metoprolol | 2021 |
THE SAFETY AND EFFICACY OF AMIODARONE AND CARVEDILOL COMBINATION IN TREATMENT OF PATIENTS WITH SEVERE CARDIAC RHYTHM DISORDERS.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibril | 2017 |
Effects of carvedilol therapy on cardiac autonomic control, QT dispersion, and ventricular arrhythmias in children with dilated cardiomyopathy.
Topics: Arrhythmias, Cardiac; Autonomic Nervous System; Carbazoles; Cardiomyopathy, Dilated; Carvedilol; Chi | 2013 |
Differential effects of the β-adrenoceptor blockers carvedilol and metoprolol on SQT1- and SQT2-mutant channels.
Topics: Action Potentials; Adrenergic beta-Antagonists; Animals; Arrhythmias, Cardiac; Carbazoles; Carvedilo | 2013 |
Dose Related Patterns of Ventricular Arrhythmia due to Carvedilol Withdrawal in Patients with Systolic Heart Failure.
Topics: Adrenergic beta-Antagonists; Aged; Arrhythmias, Cardiac; Carbazoles; Carvedilol; Dose-Response Relat | 2015 |
Successful treatment of arrhythmia-induced cardiomyopathy in an infant with tuberous sclerosis complex.
Topics: Adrenergic beta-Antagonists; Arrhythmias, Cardiac; Carbazoles; Cardiomyopathy, Dilated; Carvedilol; | 2016 |
Nebivolol suppresses cardiac ryanodine receptor-mediated spontaneous Ca2+ release and catecholaminergic polymorphic ventricular tachycardia.
Topics: Adrenergic beta-1 Receptor Agonists; Adrenergic beta-Antagonists; Animals; Arrhythmias, Cardiac; Cal | 2016 |
Carvedilol ameliorates sympathetic nerve sprouting and electrical remodeling after myocardial infarction in rats.
Topics: Action Potentials; Adrenergic beta-Antagonists; Animals; Arrhythmias, Cardiac; Autonomic Pathways; C | 2010 |
Carvedilol and its new analogs suppress arrhythmogenic store overload-induced Ca2+ release.
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Bisoprolol; Calcium; Calci | 2011 |
Carvedilol tweaks calcium release to ease arrhythmias.
Topics: Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Calcium; Calcium Channel Blockers; Carbazoles | 2011 |
COMET: a proposed mechanism of action to explain the results and concerns about dose.
Topics: Adenosine Triphosphatases; Adrenergic beta-Antagonists; Arrhythmias, Cardiac; Carbazoles; Carvedilol | 2003 |
AVID and COMET.
Topics: Adrenergic beta-Antagonists; Arrhythmias, Cardiac; Carbazoles; Carvedilol; Heart Conduction System; | 2003 |
[Correction of baroreflex sensitivity impairment and efficacy of prevention of sudden arrhythmic death in patients with postinfarction left ventricular dysfunction].
Topics: Adrenergic beta-Antagonists; Adult; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti | 2004 |
Three decades of clinical trials with beta-blockers: the contribution of the CAPRICORN trial and the effect of carvedilol on serious arrhythmias.
Topics: Adrenergic beta-Antagonists; Arrhythmias, Cardiac; Carbazoles; Carvedilol; Clinical Trials as Topic; | 2005 |
Tolerability of beta-blockers in outpatients with refractory heart failure who were receiving continuous milrinone.
Topics: Adrenergic beta-Antagonists; Aged; Arrhythmias, Cardiac; Blood Pressure; Carbazoles; Cardiac Output, | 2007 |
Case 36-2007: a woman with rash, fever, and hypotension.
Topics: Adrenergic beta-Antagonists; Arrhythmias, Cardiac; Carbazoles; Carvedilol; Female; Humans; Hypotensi | 2008 |
Carvedilol--a wide therapeutic potential in cardiovascular syndromes. Introduction.
Topics: Adrenergic beta-Antagonists; Arrhythmias, Cardiac; Carbazoles; Carvedilol; Free Radical Scavengers; | 1993 |
Beta-blockers and ventricular arrhythmias in dilated cardiomyopathy.
Topics: Adrenergic beta-Antagonists; Arrhythmias, Cardiac; Carbazoles; Cardiomyopathy, Dilated; Carvedilol; | 2000 |
The inhibitory effects of carvedilol against arrhythmias induced by coronary reperfusion in anesthetized rats.
Topics: Adrenergic beta-Antagonists; Anesthesia, General; Animals; Arrhythmias, Cardiac; Carbazoles; Carvedi | 2000 |